ApoB 71 mg/dL
ApoB and LDL particle burden
Cardiometabolic risk is improving, but the trend stays paired with CAC history and family risk instead of being read as one isolated lab.
Synthetic lab panel, 2026-03-18
Fictional public demo patient
Daniel Stone
A synthetic longevity profile built to demonstrate Dr. Judah without exposing any real private health record or calling live AI for logged-out users.
Extend healthspanReduce cardiometabolic riskProtect sleep quality
ApoB · trend over time
Dr. Judah reads each biomarker as a trajectory against its target range — not a single isolated result.
71mg/dLin range
8 readings · Apr 2018–Mar 2026 · -41 since firstHbA1c5.4%
hs-CRP0.6 mg/L
Resting HR52 bpm
Ask Dr. Judah · sample
IllustrativeIs my cardiovascular risk actually improving, or am I reading too much into one lab?
DJ
Your trajectory is genuinely improving, and it holds up across more than one marker. ApoB has fallen from 112 to 71 mg/dL since 2018[1] — now inside your <90 target — and hs-CRP has come down to 0.6 mg/L[2], so particle burden and the inflammatory signal are trending down together. I'd keep reading this alongside your CAC history rather than treating any single ApoB result as the whole story.
Sources
1
Lipid panel
ApoB 71 mg/dL · 2026-03-18
2
Inflammation
hs-CRP 0.6 mg/L · 2026-03-01
Sample answer over synthetic data. Live Ask draws only on your own saved records and cites the exact sources behind each response — available after sign-in.
Sleep score 84
Sleep recovery signal
Sleep depth recovered after travel, with resting heart rate returning to baseline across the trailing wearable window.
Synthetic wearable summary, trailing 14 days
Time in range 96%
Glucose stability
Post-meal glucose excursions are controlled; late meals still correlate with higher overnight variability.
Synthetic CGM summary, trailing 10 days
SLCO1B1 watch
Genomics-aware medication note
The demo context shows how a medication discussion can preserve pharmacogenomic cautions without turning them into a diagnosis.
Synthetic 23andMe-derived medication context